DILIsym® v5A Released
RESEARCH TRIANGLE PARK, NC – DILIsym Services Inc. (www.dilisymservices.com) announces the release of DILIsym® v5A. DILIsym® software is developed and released as part of the DILI-sim Initiative (www.dilisym.com), an effort to develop a mathematical, mechanistic model of drug-induced liver injury chaired by Dr. Paul B. Watkins. DILIsym® v5A was made available to all DILI-sim Initiative industry members as of July 18, 2016.
DILIsym® v5A introduces several new validation compounds, including TAK875 (Takeda), MK0536 (Merck), CKA (AstraZeneca), and AMG853 (Amgen). A new mechanism of toxicity, mitochondrial DNA depletion has been added, with fialuridine (FIAU) as the exemplar compound. A mechanistic representation of bilirubin transport and metabolism has been added, with indinavir and CKA as exemplar compounds. DILIsym® v5A also features a non‑alcoholic fatty liver disease (NAFLD) SimPops™.
ABOUT THE DILI-SIM INITIATIVE
The DILI-sim Initiative is a pre-competitive partnership between DILIsym Services Inc. and a diverse set of stakeholders to develop a computational model that will predict whether new drug candidates will cause drug-induced liver injury (DILI) in patients. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. It is the intent of the DILI-sim Initiative to make the model, in the form of DILIsym® software, broadly available so that it may be used by the pharmaceutical industry and other entities in academia, government, and industry. The Initiative is led by Dr. Paul B. Watkins, Director of the University of North Carolina Institute for Drug Safety Sciences, located in the heart of Research Triangle Park, North Carolina. For more information, please visit www.dilisym.com.
ABOUT DILISYM SERVICES INCORPORATED
DILIsym Services, Inc. was incorporated in 2015 and is operated in Research Triangle Park, North Carolina. DILIsym Services, Inc. is a startup company committed to providing the pharmaceutical industry with the tools, resources, and information to efficiently develop safer drug therapies that increase the availability of vital therapeutics for the patients who need them. DILIsym Services, Inc.applies the DILIsym® software to improve the safety profiles of therapeutics reaching the market.
For more information, please visit www.dilisymservices.com
DILIsym® v5A introduces several new validation compounds, including TAK875 (Takeda), MK0536 (Merck), CKA (AstraZeneca), and AMG853 (Amgen). A new mechanism of toxicity, mitochondrial DNA depletion has been added, with fialuridine (FIAU) as the exemplar compound. A mechanistic representation of bilirubin transport and metabolism has been added, with indinavir and CKA as exemplar compounds. DILIsym® v5A also features a non‑alcoholic fatty liver disease (NAFLD) SimPops™.
ABOUT THE DILI-SIM INITIATIVE
The DILI-sim Initiative is a pre-competitive partnership between DILIsym Services Inc. and a diverse set of stakeholders to develop a computational model that will predict whether new drug candidates will cause drug-induced liver injury (DILI) in patients. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. It is the intent of the DILI-sim Initiative to make the model, in the form of DILIsym® software, broadly available so that it may be used by the pharmaceutical industry and other entities in academia, government, and industry. The Initiative is led by Dr. Paul B. Watkins, Director of the University of North Carolina Institute for Drug Safety Sciences, located in the heart of Research Triangle Park, North Carolina. For more information, please visit www.dilisym.com.
ABOUT DILISYM SERVICES INCORPORATED
DILIsym Services, Inc. was incorporated in 2015 and is operated in Research Triangle Park, North Carolina. DILIsym Services, Inc. is a startup company committed to providing the pharmaceutical industry with the tools, resources, and information to efficiently develop safer drug therapies that increase the availability of vital therapeutics for the patients who need them. DILIsym Services, Inc.applies the DILIsym® software to improve the safety profiles of therapeutics reaching the market.
For more information, please visit www.dilisymservices.com